One of these is made from your own blood in the room. The other is manufactured in a factory and approved by the FDA. Ez Gel is an autologous preparation. Your blood is drawn and spun in a centrifuge. Part of it is then heated to form an injectable gel. Sculptra is poly-L-lactic acid, a synthetic polymer supplied as a sterile freeze-dried powder.
That difference decides almost everything else on this page. It decides what a regulator has looked at. It decides how predictable each dose is, how long each lasts, and what is left in your face afterwards.
There is no FDA-approved or cleared injectable filler product called Ez Gel. The material is made from the patient's own blood at the point of care. So there is no product to approve. The centrifuge or kit used may hold its own clearance for preparing blood components. But a clearance for a preparation device is not approval of a cosmetic treatment. Sculptra is different. It is a Class III device approved through premarket approval, PMA P030050, with named indications and trials the FDA reviewed.
Autologous does not mean risk-free, and manufactured does not mean unsafe. Both are injected into a face. Anything injected into a face can enter an artery. Neither has an antidote.
The published protocol describes combining denatured albumin, spun at 2,600 rpm for 7 minutes, with liquid platelet-rich fibrin spun at 1,100 rpm for 5 minutes, in roughly a 3.5 to 1.5 cc ratio, to form an injectable gel. Heating the albumin is what turns it into a gel.
The current US labelling describes 367.5 mg of freeze-dried powder per vial containing poly-L-lactic acid microparticles with sodium carboxymethylcellulose and mannitol, reconstituted with 5 mL or 8 mL of sterile water.
There is no product specification, no lot number and no label, because there is no product - only a process. Two clinics using the same name may not be producing the same gel.
The dilution, the depth and the maximum volume per area are all written down in documents anyone can read.
No FDA-approved or cleared injectable filler by this name exists, and no clearance covers an Ez Gel kit for aesthetic injection. A clearance number quoted for it will be for something else.
Facial fat loss in people with HIV (3 August 2004), shallow to deep nasolabial fold contour deficiencies and other facial wrinkles suited to a deep dermal cross-hatch technique (2009), and fine lines and wrinkles in the cheek region (2023).
The main article describing the periocular use is a technique and expert-opinion paper with prospective observations, not a controlled trial. Its senior author is medical director of a company that manufactures and distributes platelet-rich fibrin gel kits.
The 2009 nasolabial fold trial randomized 233 people against a collagen comparator with an extension to month 25. The 2023 cheek trial randomized 149 people at 13 US sites against no treatment: 70.7% responders at month 12 against 25.9%, p<0.0001. Both were sponsored by the manufacturer.
In a mouse study run to an international biocompatibility standard, standard platelet-rich fibrin membranes were substantially or completely resorbed by 21 days while the albumin version stayed volume-stable through the study. A review of the technique reports that a ten-minute heating step extends resorption from the usual two to three weeks to at least four months in a subcutaneous animal model. Those authors run a commercial education business in this field.
Wrinkle scores stayed stable or improved to month 25 in the 2009 extension, and the 2023 trial reported 76.9% responders at months 21 and 24 in its previously treated group.
The technique paper positions it for people wanting a conservative approach, particularly those with previous hyaluronic acid complications or poor lymphatic drainage in the area.
The under-eye area is not one of them. Sculptra is injected into the deep dermis with a threading technique.
The material is your own protein and it is resorbed. That is the genuine advantage of this side, and it is a fair reason to try it first if you are undecided.
The particles break down over roughly two years. The collagen built around them stays, and it cannot be removed either.
Being autologous genuinely removes a whole class of problems. There is no foreign polymer for the body to wall off. So the late granulomas and stubborn foreign-body nodules that appear in the poly-L-lactic acid literature have no material to form around. That is a real advantage. It should not be talked down.
What it does not do is make the injection safe. The serious risk of any facial injection is that material enters an artery. That risk comes from the needle and the anatomy, not from what is in the syringe. Blood-derived preparations and poly-L-lactic acid both appear in the published reviews of blindness after facial injection. In the 2024 review of 511 cases spanning a century, they sit together in an "other" category making up 3.4% of the 365 newly identified cases. Those reviews are case counts with no denominator. They cannot be turned into a chance of it happening to you. They do establish that neither material is exempt.
Being autologous also removes the safety net that comes with approval. There is no reviewed label, no agreed maximum volume and no defined depth. There is no adverse event reporting route attached to a product. The whole treatment is a process performed in a room. Its quality is entirely the injector's.
This is the part most clinic pages skip, so it is worth setting out plainly.
The idea behind heating the albumin is straightforward. Ordinary platelet-rich fibrin is resorbed quickly. Heating denatures the albumin, so the gel lasts longer. The evidence for that is animal evidence. In a mouse study run to an international biocompatibility standard, standard platelet-rich fibrin membranes were substantially or completely resorbed by 21 days while the albumin version remained volume-stable through the study. The family of techniques goes by several names: albumin gel, Bio-Heat, Alb-PRF and others. A review of it reports that a ten-minute heating step extends resorption from the usual two to three weeks to at least four months. That was in a subcutaneous animal model.
Two things follow. First, that is a resorption timescale in animals, not a duration of visible cosmetic result in people. Second, the authors of both the technique paper and the review have commercial interests in this space. The senior author of the periocular technique paper is medical director of a company that makes and distributes platelet-rich fibrin gel kits. The review authors run a commercial education business built on the technique. That does not make the findings wrong. It does mean nobody independent has confirmed them in patients.
The human aesthetic evidence is thinner still. The main published account of the periocular use is a technique article with prospective observations, not a controlled trial.
The trade runs both ways, and this page should be honest about the other side.
Sculptra puts a synthetic polymer into your face on purpose. It works precisely because the body reacts to it. Laboratory work comparing immune cells exposed to poly-L-lactic acid found that it triggers inflammatory signalling. That study was run by researchers at a company that makes a competing product, so read it with that in mind. The mechanism itself is not controversial. The treatment is a controlled foreign-body response.
The characteristic problem that follows is a foreign-body nodule, and it can be late: papules or nodules occurred in 17.2% of the Sculptra group in the 2009 nasolabial fold trial, and the labelling records nodules beginning at a median of 160 days. That is the whole category of problem an autologous preparation does not have, because there is no polymer for tissue to wall off.
And it cannot be undone. Hyaluronidase breaks down hyaluronic acid. It does nothing to poly-L-lactic acid. No reversal agent is approved, and the labelling does not mention one. For a lump the published options are time, saline infiltration with mechanical disruption, steroid injection, antibiotics if a biofilm is suspected, and surgery in refractory cases.
Sculptra's labelling was also updated in 2023 with information about delayed inflammation at the injection site following a viral or bacterial illness, vaccination or a dental procedure. If any of those are coming up, say so before you book.
There is no published trial of Sculptra against an albumin-and-fibrin gel, or against any blood-derived preparation, for facial rejuvenation. The two evidence bases do not touch each other, and lining up a responder rate from a randomized cheek trial against a resorption figure from a mouse model would not be a comparison of anything.
The defensible statement is about what has been documented, not about which works better. Sculptra has randomized, evaluator-blinded trials with validated wrinkle scales, a public label, and follow-up past two years, all generated by its manufacturer. Ez Gel has a described preparation protocol, animal resorption data, and expert opinion.
Go to an emergency department or call 911 for any of these after either treatment:
Sudden change or loss of vision in either eye
Sudden severe pain, or pain out of proportion to the procedure
Skin turning white or blanched, then dusky, grey or mottled
Weakness, drooping, slurred speech or any stroke-like symptom
These can mean material has entered an artery, and the window is measured in hours. Neither of these products has an antidote, so how quickly you are assessed is the only thing anyone can influence. Do not use pain as your gate - in a survey of experienced injectors describing their own intravascular injections, pain was mild or absent in 47% of events.
Swelling keeps increasing after the first few days instead of settling
A firm lump appears under the skin, whether at three weeks or at six months
Redness spreads outward from a treated area, or you develop a fever
An area becomes tender or swollen weeks later, particularly after an illness, a vaccination or dental work
One side starts to look different from the other as a Sculptra course builds